KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $95.7 million.

  • Castle Biosciences' Total Liabilities rose 3024.08% to $95.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.7 million, marking a year-over-year increase of 3024.08%. This contributed to the annual value of $75.4 million for FY2024, which is 2147.38% up from last year.
  • Latest data reveals that Castle Biosciences reported Total Liabilities of $95.7 million as of Q3 2025, which was up 3024.08% from $89.4 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Total Liabilities peaked at $95.7 million during Q3 2025, and registered a low of $18.7 million during Q1 2021.
  • Over the past 5 years, Castle Biosciences' median Total Liabilities value was $50.2 million (recorded in 2023), while the average stood at $52.9 million.
  • Per our database at Business Quant, Castle Biosciences' Total Liabilities tumbled by 5533.88% in 2021 and then soared by 15120.83% in 2022.
  • Castle Biosciences' Total Liabilities (Quarter) stood at $50.8 million in 2021, then fell by 5.22% to $48.2 million in 2022, then rose by 28.83% to $62.1 million in 2023, then rose by 21.47% to $75.4 million in 2024, then increased by 26.98% to $95.7 million in 2025.
  • Its Total Liabilities was $95.7 million in Q3 2025, compared to $89.4 million in Q2 2025 and $61.4 million in Q1 2025.